Related Experiment Videos
CD95 ligand: lethal weapon against malignant glioma?
M Weller1, P Kleihues, J Dichgans
1Department of Neurology, University of Tübingen, Germany. michael.weller@uni-tuebingen.de
Brain Pathology (Zurich, Switzerland)
|April 18, 1998
Summary
CD95 (Fas/APO-1) expression increases in malignant gliomas and can induce apoptosis. Targeting CD95 offers a promising therapeutic strategy for glioblastoma, potentially sparing normal brain tissue.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- CD95 (Fas/APO-1) and CD95 Ligand (CD95L) are key regulators of apoptosis.
- CD95 expression is elevated in malignant gliomas, particularly glioblastoma, and correlates with tumor progression.
- Hypoxia or ischemia do not appear to trigger CD95 expression in malignant gliomas.
Purpose of the Study:
- To investigate the role of CD95/CD95L pathway in malignant glioma apoptosis.
- To evaluate CD95 as a potential therapeutic target for glioblastoma treatment.
Main Methods:
- In vitro studies using human malignant glioma cells.
- Assessment of CD95 expression levels and sensitivity to apoptosis-inducing agents.
- Analysis of intracellular apoptosis-regulatory proteins, including bcl-2 family members.
Main Results:
- Agonistic antibodies to CD95 or CD95L induce apoptosis in glioma cells in vitro.
- Glioma cell apoptosis sensitivity is influenced by cell surface CD95 levels and intracellular proteins.
- Cytotoxic drugs synergize with CD95L to enhance glioma cell killing.
- Glioma cells kill T cells via CD95/CD95L but are resistant to fratricide in vitro.
- CD95L is expressed in gliomas in vivo.
Conclusions:
- Forced induction of CD95 expression may promote therapeutic apoptosis in malignant gliomas.
- Selective CD95 agonists could offer high antitumor activity against gliomas while sparing normal brain tissue.
- CD95 represents a promising therapeutic target for malignant glioma treatment.